Highlights from AAN 2021: Multiple Sclerosis – eBook
AAN 2021 MS Neurov2.indd Featuring A Potential Mechanism to Target in Progressive MS Targeting CNS...
AAN 2021
PhysQuiz on AAN 2021: Multiple Sclerosis
Are you caught up on trials on multiple sclerosis that have been released from AAN 2021? Test your...
Neurofilament light outperforms total tau as biomarker for neurodegeneration
Plasma neurofilament light chain (NfL) demonstrated to be a more valuable biomarker for neurodegeneration than total tau (T-tau) protein. This was the conclusion of the Mayo Clinic Study of Aging (MCSA), comparing the 2...
sNfL projects development of definite MS
In patients who experienced a first clinical demyelinating event, baseline levels of serum neurofilament light chain (sNfL), a biomarker of neural damage, were associated with conversion to McDonald 2005 multiple sclerosis (MS)....
Mast cell and neutrophil involvement in the disease activity of MS
Preliminary results of a genome-wide-association study (GWAS) show a possible involvement of mast cells and neutrophils in the disease activity of relapsing-remitting MS patients [1]. These results provide important knowledge on...
The role of brain ATP abnormalities in MS disease progression
A 3-year prospective observational study investigating ATP changes in MS via T7 MRSI, comparing patients with and without vascular disease risk factors (VDRF), demonstrated that VDRF-positive patients had lower brain ATP rates...
MS disease-modifying therapies influence COVID-19 infection severity
MS patients treated with anti-CD20 therapies ocrelizumab and rituximab have an increased risk of severe COVID-19 infection, whereas treatment with interferon or teriflunomide could reduce that risk. These were the preliminary...
AAN 2021: Central & Peripheral Neurological Symptoms in PIMS-TS
Despite reports of neurological manifestations in both children and adults with COVID-19, the neurological manifestations of children with recently described severe post‐infectious immune‐mediated disorder pediatric inflammatory...
AAN 2021: Depression & Anxiety Inversely Associated With Alzheimer’s Disease Age of Onset
While evidence indicates depression as a risk factor for Alzheimer’s disease (AD) that may accelerate development and progression, the effects of other psychiatric disease on AD as less well known. For a study, researchers...
AAN 2021: Plasma Neurofilament Light a Solid Prognostic Marker of Neurodegeneration
Previous studies indicate that elevated plasma total tau (T-tau) and neurofilament light (NfL) are, cross-sectionally and longitudinally, associated with worse cognition and neuroimaging measures of cortical thickness, cortical...
AAN 2021: Neurological Dysfunction Negatively Impacts COVID-19 Outcomes
Although emerging data indicate that various neurological symptoms are associated with COVID-19, data are lacking on the outcomes of patients with neurological dysfunctions who acquire COVID-19. To determine these outcomes,...
AAN 2021: Telestroke System Accurately Assesses Variety of Neurologic Syndromes
With 50% mimic rates in prior studies, telestroke consultation may be able to provide an early, accurate diagnosis to patients with stroke mimics, thus avoiding unnecessary treatments and transfers. However, data are lacking on...
